Within this framework, an approach of NIR-PIT for prostate cancer was recently proposed by Kobayashi and collogues, describing the synthesis of an anti-PSMA antibody conjugated with IR700, e.g., anti-PSMA-IR700 (Nagaya et al., 2017). Here, FOLH1 is linked to prostate cancer.